Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

CROPseq-iT7
(Plasmid #211699)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 211699 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.

Backbone

  • Vector backbone
    CROPseq
  • Backbone manufacturer
    Christoph Bock
  • Backbone size (bp) 10237
  • Modifications to backbone
    Inserted an inverted T7 promoter downstream of the sgRNA terminator
  • Vector type
    Mammalian Expression, Lentiviral, CRISPR
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Please visit https://doi.org/10.1101/2024.01.18.576210 for bioRxiv preprint.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    CROPseq-iT7 was a gift from Jonathan Schmid-Burgk (Addgene plasmid # 211699 ; http://n2t.net/addgene:211699 ; RRID:Addgene_211699)
  • For your References section:

    Cell Type-Agnostic Optical Perturbation Screening Using Nuclear In-Situ Sequencing (NIS-Seq). Fandrey CI, Konopka P, Jentzsch M, Zackria AA, Maasewerd S, Latz E, Schmid-Burgk JL. bioRxiv 2024.01.18.576210 10.1101/2024.01.18.576210